Lv1
70 积分 2021-10-29 加入
Based on ARASENS trial: efficacy and safety of darolutamide as an emerging option of endocrinotherapy for metastatic hormone-sensitive prostate cancer-an updated systematic review and network meta-analysis
6天前
已完结
Preliminary Efficacy, Tolerability, and Safety Analysis of Darolutamide for Metastatic Castration-Resistant Prostate Cancer: A Single-Center, Open-Label Study
6天前
已完结
Neoadjuvant darolutamide plus androgen deprivation therapy for high-risk and locally advanced prostate cancer: a multicenter, open-label, single-arm, phase II trial
6天前
已完结
Neoadjuvant darolutamide plus androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: A multicenter, open-labeled, single-arm phase II trial
14天前
已关闭
Total Neoadjuvant Therapy With PD-1 Blockade for High-Risk Proficient Mismatch Repair Rectal Cancer
3个月前
已完结
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response
3个月前
已完结
Nonoperative Management of Mismatch Repair–Deficient Tumors
3个月前
已完结
Short-course-based TNT with or without PD-1 inhibitor for pMMR locally advanced rectal cancer: Phase 2 results of a randomized trial (STELLAR II)
3个月前
已完结
Preoperative Short-Course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor Administration for Locally Advanced Rectal Cancer: The Initial Results of a Randomized Phase II/III Trial (STELLAR II study)
3个月前
已完结
NICHE-2 validates the efficacy of neoadjuvant ICIs in dMMR colon cancer
4个月前
已完结
皖公网安备34019202002308
